15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $4.0B | -$144M | 0.0% | 0.6% | $518M | — | $214M |
| 2024 | $4.0B | $22M | 0.0% | 5.6% | $502M | — | $195M |
| 2023 | $4.1B | $475M | 0.0% | 14.9% | $365M | — | $277M |
| 2022 | $4.0B | $486M | 0.0% | 16.4% | $295M | — | $234M |
| 2021 | $3.5B | $391M | 0.0% | 16.7% | $532M | — | $241M |
| 2020 | $2.9B | $364M | 0.0% | 14.8% | $380M | — | $228M |
| 2019 | $2.6B | $252M | 0.0% | 13.4% | $340M | — | $238M |
| 2018 | $2.3B | $226M | 0.0% | 14.6% | $301M | $1.6B | $195M |
| 2017 | $1.9B | $123M | 84.4% | 15.5% | $236M | $1.1B | $164M |
| 2016 | $1.7B | $155M | 83.5% | 14.1% | $262M | $1.2B | $118M |
| 2015 | — | $149M | — | — | — | $814M | $118M |
| 2014 | — | $127M | — | — | — | $717M | $160M |
| 2013 | — | $103M | — | — | — | $663M | $156M |
| 2010 | — | -$337M | — | — | — | $701M | $179M |
| 2009 | — | $114M | — | — | — | — | $183M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $996M | -$15M | 0.0% | 12.0% | -$15M | — | $192M |
| Dec '25 | $994M | -$277M | 0.0% | -28.5% | $59M | — | $214M |
| Sep '25 | $1.0B | $54M | 0.0% | 13.3% | $178M | — | $207M |
| Jun '25 | $1.0B | $52M | 0.0% | 9.7% | $169M | — | $183M |
| Mar '25 | $984M | $25M | 0.0% | 7.6% | $112M | — | $229M |
| Dec '24 | $1.0B | -$214M | 0.0% | -16.7% | $84M | — | $195M |
| Sep '24 | $1.0B | $70M | 34.6% | 11.6% | $213M | — | $210M |
| Jun '24 | $1.0B | $94M | 34.5% | 14.8% | $154M | — | $179M |
| Mar '24 | $1.0B | $73M | 34.1% | 12.5% | $51M | — | $327M |
| Dec '23 | $1.0B | $187M | 0.0% | 13.1% | $143M | — | $277M |
| Sep '23 | $1.0B | $87M | 35.2% | 14.8% | $140M | — | $157M |
| Jul '23 | $1.1B | $97M | 37.6% | 15.6% | $81M | — | $200M |
| Apr '23 | $1.0B | $103M | 36.7% | 16.3% | $3M | — | $202M |
| Dec '22 | $1.1B | $187M | 0.0% | 14.9% | $146M | — | $234M |
| Sep '22 | $989M | $96M | 0.0% | 15.3% | $60M | — | $194M |
| Jun '22 | $973M | $109M | 0.0% | 19.3% | $67M | — | $200M |
| Mar '22 | $914M | $93M | 0.0% | 16.3% | $22M | — | $242M |
| Dec '21 | $905M | $138M | 0.0% | 19.1% | $130M | — | $241M |
| Sep '21 | $896M | $103M | 0.0% | 17.4% | $119M | — | $213M |
| Jun '21 | $915M | $88M | 0.0% | 15.0% | $140M | — | $223M |
How the market has priced CRL against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Charles River Laboratories's revenue has grown 6.5% per year. These are computed facts, not advice.
As of FY2025, Charles River Laboratories reported — of total debt against $214M of cash; operating income covered interest expense 0.2×.
In FY2025, gross margin was —, operating margin 0.6%, and net margin -3.6%.
As of Jun '26, Charles River Laboratories traded at a price-to-earnings ratio of about 386.3× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.